Interesting Call
They said a number of interesting things in this call. One was two CR's in H&N maybe I was asleep on past conference calls but i only remember one in the past. Anyone have another recollection? With the number of treated patients with Taxane's in the US study, it gives me added confidence that the lower results compared to the UK trial is fully explained in my mind. It was interesting that in the question session they even said that some centers said the would change their first line protocol so that failed patients could receive reolysin and Taxane's in the phase III for second line patients.
Brad is definitely backing off from having 80m patients by the end of the year. For whatever reason we will not get there until early next year and results probable a couple months later.
With the plans for Pancreatic and Lung and added centers for phase two's and our phase three will will have to raise money early next year without a partnership, IMHO. Hopefully it will come after the report on the first 80 at a much better stock price.